TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES
4.2.2 ADVANCEMENTS IN TECHNOLOGY AND ANALYTICAL TECHNIQUES
4.2.3 STRONG HEALTHCARE INFRASTRUCTURE
4.3 RESTRAINTS
4.3.1 SHORTAGE OF SKILLED AND EXPERIENCED PROFESSIONALS
4.4 OPPORTUNITY
4.4.1 GROWING POPULARITY OF PERSONALIZED MEDICINE
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 CUSTOMER ACQUISITION (PREPURCHASE QUERY)
5.1.2 SERVICE CUSTOMIZATION
5.1.3 CUSTOMER PURCHASE SUPPORT
5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON PRICING
5.3.3 IMPACT ON KEY PLAYERS
6 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY SERVICE TYPE
6.1 OVERVIEW
6.2 PHARMACOKINETIC SERVICES
6.2.1 DRUG ABSORPTION STUDIES
6.2.2 DRUG DISTRIBUTION STUDIES
6.2.3 DRUG METABOLISM STUDIES
6.2.4 DRUG EXCRETION STUDIES
6.2.5 OTHERS
6.3 PHARMACODYNAMIC SERVICES
6.3.1 RECEPTOR BINDING STUDIES
6.3.2 BIOMARKER ANALYSIS
6.3.3 OTHERS
7 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY DRUG TYPE
7.1 OVERVIEW
7.2 SMALL MOLECULES
7.3 LARGE MOLECULES
8 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY THERAPEUTIC AREA
8.1 OVERVIEW
8.2 ONCOLOGY
8.3 CARDIOVASCULAR
8.4 INFECTIOUS DISEASES
8.5 NEUROLOGY
8.6 IMMUNOLOGY
8.7 OTHERS
9 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY END USER
9.1 OVERVIEW
9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
9.3 ACADEMIC AND RESEARCH INSTITUTIONS
9.4 OTHERS
10 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY COUNTRY
10.1 OVERVIEW
10.2 NORTH AMERICA
10.3 US
10.4 CANADA
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, 2022
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
12 COMPANY PROFILES
12.1 CREATIVE BIOARRAY
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 KEY STRATEGY
12.2 QUANTICATE
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 KEY STRATEGY
12.3 PACIFIC BIOLABS, INC.
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIES
12.4 ALLUCENT
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 CHARLES RIVER LABORATORIES
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 EVOTEC AG
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA.
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 SERVICES OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIES
12.8 LGC LIMITED
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 SERVICES OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIES
12.9 EUROFINS SCIENTIFIC
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 SERVICES OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 CREATIVE BIOLABS
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 SERVICES OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.10.6 KEY STRATEGIES
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION)
TABLE 3 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACOKINETIC SERVICES, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 4 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACOKINETIC SERVICES, BY TYPE, 2019–2032 (USD MILLION)
TABLE 5 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR DRUG ABSORPTION STUDIES, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 6 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR DRUG DISTRIBUTION STUDIES, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 7 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR DRUG METABOLISM STUDIES, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 8 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR DRUG EXCRETION STUDIES, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 9 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR OTHERS, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 10 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACODYNAMIC SERVICES, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 11 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACODYNAMIC SERVICES, BY TYPE, 2019–2032 (USD MILLION)
TABLE 12 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR RECEPTOR BINDING STUDIES, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 13 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 14 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR OTHERS, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 15 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY DRUG TYPE, 2019–2032 (USD MILLION)
TABLE 16 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR SMALL MOLECULES, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 17 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR LARGE MOLECULES, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 18 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY THERAPEUTIC AREA, 2019–2032 (USD MILLION)
TABLE 19 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR ONCOLOGY, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 20 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR CARDIOVASCULAR, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 21 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 22 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR NEUROLOGY, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 23 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR IMMUNOLOGY, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 24 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR OTHERS, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 25 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 26 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 27 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 28 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR OTHERS, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 29 NORTH AMERICA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 30 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION)
TABLE 31 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACOKINETIC SERVICES, BY TYPE, 2019–2032 (USD MILLION)
TABLE 32 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACODYNAMIC SERVICES, BY TYPE, 2019–2032 (USD MILLION)
TABLE 33 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY DRUG TYPE, 2019–2032 (USD MILLION)
TABLE 34 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY THERAPEUTIC AREA, 2019–2032 (USD MILLION)
TABLE 35 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY END USER, 2019–2032 (USD MILLION)
TABLE 36 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION)
TABLE 37 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACOKINETIC SERVICES, BY TYPE, 2019–2032 (USD MILLION)
TABLE 38 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACODYNAMIC SERVICES, BY TYPE, 2019–2032 (USD MILLION)
TABLE 39 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY DRUG TYPE, 2019–2032 (USD MILLION)
TABLE 40 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY THERAPEUTIC AREA, 2019–2032 (USD MILLION)
TABLE 41 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY END USER, 2019–2032 (USD MILLION)
TABLE 42 PUBLIC PLAYERS STOCK SUMMARY
TABLE 43 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 44 CREATIVE BIOARRAY: PRODCUTS OFFERED
TABLE 45 QUANTICATE: SERVICES OFFERED
TABLE 46 PACIFIC BIOLABS, INC.: SERVICES OFFERED
TABLE 47 ALLUCENT: SERVICES OFFERED
TABLE 48 CHARLES RIVER LABORATORIES: SERVICES OFFERED
TABLE 49 EVOTEC AG: SERVICES OFFERED
TABLE 50 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: SERVICE OFFERED
TABLE 51 LGC LIMITED: SERVICES OFFERED
TABLE 52 EUROFINS SCIENTIFIC: SERVICES OFFERED
TABLE 53 Creative Biolabs: services Offered 
LIST OF FIGURES
FIGURE 1 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET: STRUCTURE
FIGURE 2 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)
FIGURE 5 VALUE CHAIN ANALYSIS OF THE NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET
FIGURE 6 PORTER’S FIVE FORCES ANALYSIS: NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET
FIGURE 7 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, SERVICE TYPE SEGMENT ATTRACTIVENESS, 2019-2032 (USD MILLION)
FIGURE 8 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY SERVICE TYPE, 2022 & 2032 (USD MILLION)
FIGURE 9 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY SERVICE TYPE, 2022
FIGURE 10 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, DRUG TYPE SEGMENT ATTRACTIVENESS, 2019-2032 (USD MILLION)
FIGURE 11 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY DRUG TYPE, 2022 & 2032 (USD MILLION)
FIGURE 12 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY DRUG TYPE, 2022
FIGURE 13 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, THERAPEUTIC AREA SEGMENT ATTRACTIVENESS, 2019-2032 (USD MILLION)
FIGURE 14 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY THERAPEUTIC AREA, 2022 & 2032 (USD MILLION)
FIGURE 15 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY THERAPEUTIC AREA, 2022
FIGURE 16 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, END USER SEGMENT ATTRACTIVENESS, 2019-2032 (USD MILLION)
FIGURE 17 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY END USER, 2022 & 2032 (USD MILLION)
FIGURE 18 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY END USER, 2022
FIGURE 19 NORTH AMERICA MARKET ANALYSIS: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, 2019-2032 (USD MILLION)
FIGURE 20 NORTH AMERICA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION)
FIGURE 21 NORTH AMERICA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 22 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET PLAYERS: COMPETITIVE ANALSIS, 2022
FIGURE 23 COMPETITOR DASHBOARD: NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET
FIGURE 24 ALLUCENT: SWOT ANALYSIS
FIGURE 25 CHARLES RIVER LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 CHARLES RIVER LABORATORIES: SWOT ANALYSIS
FIGURE 27 EVOTEC AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 EVOTEC AG: SWOT ANALYSIS
FIGURE 29 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 LGC LIMITED: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 EUROFINS SCIENTIFIC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 EUROFINS SCIENTIFIC: SWOT ANALYSIS
FIGURE 33 CREATIVE BIOLABS: SWOT ANALYSIS
